In Stroke Stroke is a medical emergency that occurs due to damage to the brain. C-Colin-P Tablet helps in speeding up the recovery process in patients who have undergone stroke. It decreases brain damage, promotes healing and enhances the overall health of the patient.
It is not known whether it is safe to consume alcohol with C
P Tablet. Please consult your doctor.
Information regarding the use of C
P Tablet during pregnancy is not available. Please consult your doctor.
Information regarding the use of C
P Tablet during breastfeeding is not available. Please consult your doctor.
C
P Tablet may cause side effects which could affect your ability to drive. C
P Tablet may cause drowsiness and shakiness. This may affect your driving ability.
C
P Tablet should be used with caution in patients with kidney disease. Dose adjustment of C
P Tablet may be needed. Please consult your doctor. Use of C
P Tablet is not recommended in patients with severe kidney disease.
C
P Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of C
P Tablet may not be needed in these patients. Please consult your doctor.
If you miss a dose of C-Colin-P Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More